Exelixis, Inc. reported a significant increase in financial performance for the third quarter of 2025, with total revenues reaching $597.8 million, an 11% increase from $539.5 million in the same period last year. The company's net product revenues rose by 14% to $542.9 million, driven primarily by a 17% increase in the number of units sold of its flagship product, CABOMETYX, which is used in the treatment of advanced renal cell carcinoma and neuroendocrine tumors. The growth in revenue reflects the ongoing demand for CABOMETYX, particularly in combination with nivolumab as a first-line treatment.
In contrast, collaboration revenues decreased by 11% to $54.8 million, attributed to a decline in milestone payments and collaboration services. The company recognized $5.8 million in milestone revenues during the quarter, a significant drop from $14.6 million in the prior year, primarily due to fewer milestone achievements in its collaboration agreements. Exelixis also reported a net income of $193.6 million, or $0.72 per share, compared to $118.0 million, or $0.41 per share, in the same quarter of 2024.
Operationally, Exelixis has made strategic moves, including the appointment of Dana T. Aftab, Ph.D., as Executive Vice President of Research and Development in August 2025. The company has also been active in its stock repurchase program, having repurchased $895.3 million of its common stock as of September 30, 2025, with an additional $104.7 million remaining available for future repurchases. This initiative is part of a broader strategy to enhance shareholder value while continuing to invest in its product pipeline.
The company’s cash and cash equivalents, along with marketable securities, totaled $1.6 billion as of September 30, 2025, a decrease from $1.7 billion at the end of 2024. This decline is primarily due to stock repurchases and operational expenditures, although cash generated from product sales has increased. Exelixis anticipates that its current cash reserves, combined with projected revenues, will sustain its operations for at least the next 12 months.
Looking ahead, Exelixis remains focused on advancing its product pipeline, particularly zanzalintinib, which is currently undergoing pivotal trials for various cancer indications. The company is also navigating challenges related to market competition and regulatory changes, particularly in the context of drug pricing reforms. Despite these challenges, Exelixis is optimistic about its growth trajectory, driven by the continued success of CABOMETYX and the potential of its expanding pipeline.
About EXELIXIS, INC.
Exelixis, Inc. is an oncology-focused biopharmaceutical company developing targeted cancer therapies, primarily through its flagship molecule cabozantinib. Its core business includes marketing approved treatments for kidney, thyroid, liver, and other cancers, alongside a robust pipeline of investigational small molecules and biotherapeutics. The company leverages strategic collaborations and licensing to expand its portfolio, aiming to improve cancer patient outcomes worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.